-
Design of Trials with Composite Endpoints with the R Package CompAREdesign
Authors:
Jordi Cortés Martinez,
Marta Bofill Roig,
Guadalupe Gómez Melis
Abstract:
Composite endpoints are widely used as primary endpoints in clinical trials. Designing trials with time-to-event endpoints can be particularly challenging because the proportional hazard assumption usually does not hold when using a composite endpoint, even when the premise remains true for their components. Consequently, the conventional formulae for sample size calculation do not longer apply. W…
▽ More
Composite endpoints are widely used as primary endpoints in clinical trials. Designing trials with time-to-event endpoints can be particularly challenging because the proportional hazard assumption usually does not hold when using a composite endpoint, even when the premise remains true for their components. Consequently, the conventional formulae for sample size calculation do not longer apply. We present the R package CompAREdesign by means of which the key elements of trial designs, such as the sample size and effect sizes, can be computed based on the information on the composite endpoint components. CompAREdesign provides the functions to assess the sensitivity and robustness of design calculations to variations in initial values and assumptions. Furthermore, we describe other features of the package, such as functions for the design of trials with binary composite endpoints, and functions to simulate trials with composite endpoints under a wide range of scenarios.
△ Less
Submitted 4 November, 2022;
originally announced November 2022.
-
Decision tool and Sample Size Calculator for Composite Endpoints
Authors:
Marta Bofill Roig,
Jordi Cortés Martínez,
Guadalupe Gómez Melis
Abstract:
Summary points:
- This article considers the combination of two binary or two time-to-event endpoints to form the primary composite endpoint for leading a trial.
- It discusses the relative efficiency of choosing a composite endpoint over one of its components in terms of: the frequencies of observing each component; the relative treatment effect of the tested therapy; and the association betw…
▽ More
Summary points:
- This article considers the combination of two binary or two time-to-event endpoints to form the primary composite endpoint for leading a trial.
- It discusses the relative efficiency of choosing a composite endpoint over one of its components in terms of: the frequencies of observing each component; the relative treatment effect of the tested therapy; and the association between both components.
- We highlight the very important role of the association between components in choosing the most efficient endpoint to use as primary.
- For better grounded future trials, we recommend trialists to always reporting the association between components of the composite endpoint.
- Common fallacies to note when using composite endpoints: i) composite endpoints always imply higher power; ii) treatment effect on the composite endpoint is similar to the average effects of its components; and iii) the probability of observing the primary endpoint increases significantly.
△ Less
Submitted 10 January, 2020;
originally announced January 2020.
-
Non-constant hazard ratios in randomized controlled trials with composite endpoints
Authors:
Jordi Cortés Martínez,
Moisès Gómez Mateu,
KyungMann Kim,
Guadalupe Gómez Melis
Abstract:
The hazard ratio is routinely used as a summary measure to assess the treatment effect in clinical trials with time-to-event endpoints. It is frequently assumed as constant over time although this assumption often does not hold. When the hazard ratio deviates considerably from being constant, the average of its plausible values is not a valid measure of the treatment effect, can be clinically misl…
▽ More
The hazard ratio is routinely used as a summary measure to assess the treatment effect in clinical trials with time-to-event endpoints. It is frequently assumed as constant over time although this assumption often does not hold. When the hazard ratio deviates considerably from being constant, the average of its plausible values is not a valid measure of the treatment effect, can be clinically misleading and common sample size formulas are not appropriate.
In this paper, we study the hazard ratio along time of a two-component composite endpoint under the assumption that the hazard ratio for each component is constant.
This work considers two measures for quantifying the non-proportionality of the hazard ratio: the difference $D$ between the maximum and minimum values of hazard ratio over time and the relative measure $R$ representing the ratio between the sample sizes for the minimum detectable and the average effects. We illustrate $D$ and $R$ by means of the ZODIAC trial where the primary endpoint was progression-free survival.
We have run a simulation study deriving scenarios for different values of the hazard ratios, different event rates and different degrees of association between the components. We illustrate situations that yield non-constant hazard ratios for the composite endpoints and consider the likely impact on sample size.
Results show that the distance between the two component hazard ratios plays an important role, especially when they are close to 1. Furthermore, even when the treatment effects for each component are similar, if the two-component hazards are markedly different, hazard ratio of the composite is often non-constant.
△ Less
Submitted 25 July, 2019;
originally announced July 2019.
